Related Experiment Video

Updated: Nov 3, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Inclisiran in dyslipidemia

C E Kosmas1, A Muñoz Estrella2, A Sourlas3

  • 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, New York City, New York, USA. cekosmas1@gmail.com.

Drugs of Today (Barcelona, Spain : 1998)
|June 1, 2021
PubMed

Insights

Inclisiran, a novel siRNA therapy, offers a new approach to managing hypercholesterolemia for patients unresponsive or intolerant to statins. It effectively lowers LDL-C by targeting PCSK9 transcription, providing a promising alternative for cardiovascular disease risk reduction.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • RNA Therapeutics

Background:

  • Cardiovascular disease (CVD) remains a leading global cause of mortality.
  • Hypercholesterolemia is a primary risk factor for CVD.
  • Statins are standard treatment but have limitations including efficacy and side effects.

Purpose of the Study:

  • To review the role of inclisiran in managing hypercholesterolemia.
  • To highlight inclisiran as a novel therapeutic agent for lipid management.

Main Methods:

  • Review of scientific literature on inclisiran and hypercholesterolemia management.
  • Focus on the mechanism of action of inclisiran as a small interfering RNA (siRNA).

Main Results:

  • Inclisiran reduces LDL-C by inhibiting PCSK9 transcription, increasing LDL receptor recycling.
  • It offers an alternative for patients with statin intolerance or suboptimal response.
  • Received EU marketing authorization in December 2020.

Conclusions:

  • Inclisiran represents a significant advancement in hypercholesterolemia treatment.
  • Its unique mechanism provides a new option for reducing cardiovascular risk.
  • Further research and clinical application are expected.

Keywords:
Cardiovascular diseaseHypercholesterolemiaInclisiranMetabolic diseasesProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsSmall interfering RNA (siRNA) moleculesTreatment of lipoprotein disorders

More Related Videos

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

555
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.4K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
315
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
426
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
1.9K
Lipid Digestion01:06

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
95.9K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
254